Trial · NCT05813600
Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19
NCT05813600, Not applicable, Completed, Xiangao Jiang
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19. Trials, record NCT05813600. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05813600
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19
- NCT number
- NCT05813600
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 58 participants, actual
- Lead sponsor
- Xiangao Jiang
- Conditions
- Omicron Variant of COVID-19
- Interventions
- Nirmatrelvir/Ritonavir
- First posted
- 2023-04-14
- Last updated
- 2023-04-14
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Nasal swab COVID-19 nucleic acid tests | On days 4, 7, 9 and 11 of treatment | Patients in both groups underwent nasal swab COVID-19 nucleic acid tests on days 4, 7, 9 and 11 of treatment, and CT values were recorded (CT values of 40 for negative results). Compare the difference in the change of CT values of COVID-19 nucleic acid between two groups of patients |
| Primary | Virus turn negative | From date of randomization until the date of first documented progression, assessed up to 5 months | Compare the first negative conversion(or CT value ≥35) time of coronavirus nucleic acid between two groups |
| Primary | Hospital stays | From date of randomization until the date of first documented progression, assessed up to 5 months | Compare the difference in hospitalization time between the two groups strictly according to discharge criteria |
| Primary | Adverse drug reaction | From date of randomization until the date of first documented progression, assessed up to 5 months | Compare the adverse drug reactions during hospitalization between two groups |
| Primary | COVID-19 nucleic acid re-positive | From date of randomization until the date of first documented progression, assessed up to 5 months | After discharge, patients in both groups continued to be isolated at the isolation point for 7 days and underwent COVID-19 nucleic acid tests daily to compare the COVID-19 nucleic acid re-positive |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05813600
GET https://conductscience.org/api/trials/v1/NCT05813600/registered